EMERYVILLE, Calif.— NovaBay Pharmaceuticals, Inc. (NYSE: NBY), a biopharmaceutical company focusing on the development and commercialization of its non-antibiotic anti-infective products,announced that it has created an Optometry Advisory Board to help oversee the development, marketing and medical use of NovaBay’s i-Lid Cleanser and other eyecare products.

The five members of the new board are nationally known optometrists: Katherine M. Mostrota, OD, Center Director of Omni Eye Surgery in New York City; Arthur Epstein, OD, Director of the Dry Eye—Ocular Surface Disease Center and Director of Clinical Research at Phoenix Eye Care; William Townsend, ODin Houston, TX, and Distinguished Visiting Clinician in Residence at the University of Houston College of Optometry; Scot Morris, OD, owner and medical director of Eye Consultants of Colorado, LLC, in Conifer, CO; and Paul Karpecki, OD, head of the ocular surface disease clinic and director of clinical research at Koffler Vision Group in Lexington, Kentucky.

“The U.S. has 32,000 optometrists, who provide eyecare services to millions of Americans,” said Dr. Ron Najafi, chairman and CEO of NovaBay. “Our new board will play a vital role getting information to those optometrists about the benefits that i-Lid Cleanser offers to those patients.”

The board members have shown in their own practices that i-Lid Cleanser helps patients manage such conditions as blepharitis and dry-eye syndrome, which affect an estimated 40 million Americans.